EMEA-002079-PIP01-16-M02
Key facts
| Active substance |
Lumasiran (ALN-GO1)
|
| Therapeutic area |
Uro-nephrology
|
| Decision number |
P/0505/2021
|
| PIP number |
EMEA-002079-PIP01-16-M02
|
| Pharmaceutical form(s) |
Solution for injection
|
| Condition(s) / indication(s) |
Treatment of hyperoxaluria
|
| Route(s) of administration |
Subcutaneous use
|
| Contact for public enquiries |
Alnylam UK Limited
Tel. +1 8663300326
E-mail: clinicaltrials@alnylam.com |
| Decision type |
PM: decision on the application for modification of an agreed PIP
|